Puma Biotechnology, Inc. PBYI NASDAQ

Puma Biotechnology, Inc. (PBYI) has shown moderate revenue growth over the past 3 years, expanding from $228M to $228M (average +0.1%/yr). Net income reached $31M, reflecting exceptional earnings expansion at +770.1%/yr on average. The net profit margin is 13.6%, which is moderate. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 74.5% (high), with a -1.3pp trend over the period. With a market cap data available and MOAT composite score of 54/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (73/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 19-year history, the company was profitable in 4 of 19 years — a mixed long-term record
• INCOME (55/100, Partial) — the company is profitable but margin is below 15%
• MOAT (54/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 69/100 with 4/7 criteria passed.